Attention Laurel Patients:  The new Laurel office is open. The address is 7140 Contee Road, Suite 3500, Laurel, MD 20707….Attention Lanham/Largo Patients: Our new Largo office is now open and our Lanham location is closed permanently. Largo’s address is 9333 Healthcare Way Suite 4100 Largo, MD 20774.

HIPAA Alert:
Potential Data Breach : Learn More

Trial Protocol ID
USOR 23292_ART0380C001 *STAR*

Investigator
Danubia Hester, M.D.

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

Trial Protocol ID
USOR 22067_PRO1184-001

Investigator
John Wallmark, M.D.

Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors 

Trial Protocol ID
MCLA-128-CL01_eNRGy *RIT*

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

Trial Protocol ID
1403-0002 *RIT*

A phase Ia/Ib, open-label, dose escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors

Trial Protocol ID
1403-0001 *RIT*

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 (Brigimadlin) in Patients With Advanced or Metastatic Solid Tumors

Trial Protocol ID
1403-0011_Brightline 2 *RIT*

Brightline 2 - A Phase II/III, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type solid tumours-biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors

Trial Protocol ID
IK930-001 *RIT*

A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Trial Protocol ID
TPX-0005-07 *RIT*

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations

Trial Protocol ID
F8394-201a *RIT*

A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations

Trial Protocol ID
BO41932_TAPISTRY

Investigator
Frederick Min, M.D.

Tumor-Agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Trial Protocol ID
USOR 22052_TSC-007 *STAR*

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes 

Trial Protocol ID
USOR 19151_849-001 *STAR*

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Trial Protocol ID
USOR 22093_XB002-101_Jewel-101

A DOSE-ESCALATION AND EXPANSION STUDY OF THE SAFETY AND PHARMACOKINETICS OF XB002 AS SINGLE-AGENT AND COMBINATION THERAPY IN SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (XB002-101)

Trial Protocol ID
USOR 21367_GRAIL-012

Investigator
Jason Taksey, M.D.

The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population

Trial Protocol ID
APL-101-01_SPARTA

Investigator
Kashif Ali, M.D.

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Trial Protocol ID
USOR 18283_IMMU-132-06_TROPHY U-01

Investigator
Jun Sun, M.D.

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer

Trial Protocol ID
USOR 18283_IMMU-132-06_TROPHY U-01

Investigator
Jun Sun, M.D.

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer

Trial Protocol ID
MK 3475-158_KEYNOTE-158

Investigator
John Wallmark, M.D.

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158)

Trial Protocol ID
BO41932_TAPISTRY

Investigator
Frederick Min, M.D.

TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL

Trial Protocol ID
GCT1042-01

Investigator
Mohit Narang, M.D.

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors